AnaptysBio, Inc. (ANAB)

Over the past six months, AnaptysBio's stock price has been impacted by several events. Positive Phase 2b trial results for rosnilimab led to a significant gain. The company announced its intent to separate its biopharma operations from its royalty assets. AnaptysBio filed a partial motion to dismiss Tesaro's claim in ongoing litigation. Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab. AnaptysBio authorized stock repurchase plans and participated in various investor conferences. The stock has experienced a significant increase over the past year.

AnaptysBio's revenue is more influenced by milestone payments, royalties from out-licensed products, and its progress in clinical trials. Traditional "demand seasonality" for products or services is not directly applicable to AnaptysBio's business.

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis and ulcerative colitis, ANB101, and ANB032 for atopic dermatitis. The company has out-licensed Jemperli to GSK for oncology indications and imsidolimab to Vanda Pharmaceuticals for generalized pustular psoriasis. AnaptysBio plans to separate its biopharma operations from its royalty assets by the end of 2026.

AnaptysBio, Inc. is headquartered in San Diego, California, United States. Its primary operations involve research and development, with commercialization often handled by larger pharmaceutical partners.

AnaptysBio holds a "Moderate Buy" consensus rating from analysts, with a consensus price target of $66.89. The company has been the subject of 8 research reports in the past 90 days. Short interest in AnaptysBio has recently increased. The ongoing litigation with GSK regarding the Jemperli collaboration could also be a factor influencing its reputation. Positive clinical trial results contribute positively to the company's scientific and developmental reputation.

AnaptysBio, Inc. has substantial institutional ownership, with 287 institutional owners and shareholders holding a total of 33,565,869 shares. Major institutional owners include EcoR1 Capital, LLC, Point72 Asset Management, L.P., BlackRock, Inc., Morgan Stanley, Vanguard Group Inc, Millennium Management Llc, Tang Capital Management Llc, First Light Asset Management, LLC, State Street Corp and Sanofi.